Conference call to take place on Tuesday March 26 at 8:30 a.m. U.S Eastern
Time
HENDERSON, Nev. ,
March 21,
2024 /PRNewswire/ -- VolitionRx Limited (NYSE
AMERICAN: VNRX) ("Volition") today announced it will host a
conference call on Tuesday, March 26
at 8.30 a.m. U.S. Eastern Time to
discuss its financial and operating results for the fourth quarter
and full year 2023, in addition to providing a business update.
Details of this event can also be found below.
Event: VolitionRx Limited Fourth Quarter and Full
Year 2023 Earnings and Business Update Conference
Call
Date: Tuesday, March 26, 2024
Time: 8:30
a.m. U.S. Eastern Time
U.S. & Canada Dial-in:1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13745274
Cameron Reynolds, President and
Group Chief Executive Officer of Volition, will host the call along
with Terig Hughes, Group Chief Financial Officer, Dr. Tom Butera, Chief Executive Officer of Volition
Veterinary Diagnostics Development LLC, Dr. Andrew Retter, Chief Medical Officer, Volition
and Louise Batchelor, Group Chief
Marketing & Communications Officer. The call will provide an
update on important events which have taken place in the fourth
quarter and full year of 2023 and upcoming milestones.
A live audio webcast of the conference call will also be
available on the investor relations page of Volition's corporate
website at https://ir.volition.com. In addition, a telephone replay
of the call will be available until April 9,
2024. The replay dial-in numbers are 1-844-512-2921
(toll-free) in the U.S. and Canada
and 1-412-317-6671 (toll) internationally. Please use replay pin
number 13745274.
About Volition
Volition is a multi-national epigenetics company focused on
advancing the science of epigenetics. Volition is dedicated to
saving lives and improving outcomes for people and animals with
life-altering diseases through earlier detection, disease and
treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential to not only prolong the
life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is
included in this document as an inactive textual reference
only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
View original
content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-fourth-quarter-and-full-year-2023-earnings-conference-call-and-business-update-302095847.html
SOURCE VolitionRx Limited